Enliven Therapeutics's total assets for Q3 2024 were $305.43M, a decrease of -6.61% from the previous quarter. ELVN total liabilities were $17.03M for the fiscal quarter, a -22.99% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.